Lunaphore signs collaboration agreement with market leaders Vitro
24.05.2018
Congratulations to Venture Kick stage 3 winners Lunaphore who today announced a collaboration agreement with Spanish biotech company Vitro.
 |
 |
The companies will work together to develop In Situ Hybridization (ISH) protocols for RNA and DNA targets in tissue using reagents provided by Vitro using Lunaphore’s rapid autostaining platform. ISH is technique used to detect specific sequences of DNA or RNA in cell samples, allowing for medical diagnosis of certain pathologies that are evident in DNA and RNA, e.g. certain types of tumor.
Lunaphore’s CEO, Ata Tuna Ciftlik, said “Vitro and Lunaphore have a very good strategical fit to address ISH applications, which are a large portion of the tissue diagnostics market. Our partner Vitro can provide access to key know-how as well as quality ISH reagents, while Lunaphore has a unique automation technology”, and added: “While Lunaphore has so far focused on immunohistology, ISH applications has always remained strategically important. This collaboration indeed proves the potential of our technology to address this highly attractive market segment”.
Founded in 2014, Lunaphore is developing next generation tissue stainers using microfluids. Lunaphore won stage 3 of Venture Kick in 2015.
Lunaphore’s CEO, Ata Tuna Ciftlik, said “Vitro and Lunaphore have a very good strategical fit to address ISH applications, which are a large portion of the tissue diagnostics market. Our partner Vitro can provide access to key know-how as well as quality ISH reagents, while Lunaphore has a unique automation technology”, and added: “While Lunaphore has so far focused on immunohistology, ISH applications has always remained strategically important. This collaboration indeed proves the potential of our technology to address this highly attractive market segment”.
Founded in 2014, Lunaphore is developing next generation tissue stainers using microfluids. Lunaphore won stage 3 of Venture Kick in 2015.